Publications by authors named "Hamza Hashmi"

Claim this Profile
P
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, Andrew J Portuguese, Surbhi Sidana, Hamza Hashmi

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure.
Prerna Mewawalla, Rachel Dileo, Yue Yin, Christopher Strouse, Hira Shaikh, Hamza Hashmi

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis.
Kalyan V Nadiminti, Kwang W Ahn, Jinalben Patel, Qinghua Lian, Evandro Bezerra, Hamza Hashmi

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky, Hamza Hashmi

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.
Karen Sweiss, Charlotte Wagner, Eric Anto, Tom Greene, Ryan Sun, Hamza Hashmi

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, Ajay K Nooka, Jin Lu, Hamza Hashmi

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.
Ross S Firestone, Anish K Simhal, Devin McAvoy, Eric M Jurgens, Juan-Jose Garcés, Hamza Hashmi

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.
Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Hamza Hashmi

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Hamza Hashmi

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust CD4 CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Eric M Jurgens, Sneha Mitra, Kevin Herrera, David Nemirovsky, Brenden Bready, Hamza Hashmi

medRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.
Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, Aaron Mitchell, Ross S Firestone, Hamza Hashmi

JCO Oncol Pract· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
Ishita Kamboj, Alma Habib, Darryl Chang, Aliya Rashid, Andrew Vegel, Hamza Hashmi

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
Kai Rejeski, Jaime Sanz, Teng Fei, Monica S Nair, Hamza Hashmi

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Benjamin Adegbite, Carlyn Rose Tan, Tala Shekarkhand, Ross S Firestone, Eric M Jurgens, Hamza Hashmi

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Hamza Hashmi

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing.
Carlyn Rose Tan, Alice Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand, Hamza Hashmi

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Hamza Hashmi

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Hamza Hashmi

Transplant Cell Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Hamza Hashmi

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study.
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, Aimaz Afrough, Hamza Hashmi

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Hamza Hashmi

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse, Hamza Hashmi

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials.
Bruno Almeida Costa, Thomaz Alexandre Costa, Gabriel Cavalcante Lima Chagas, Tarek H Mouhieddine, Joshua Richter, Hamza Hashmi

Clin Lymphoma Myeloma Leuk· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel

Blood Cancer J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis